The U.S. Food and Drug Administration extended by three months its review of Pfizer Inc's experimental rheumatoid arthritis treatment tofacitinib, one of the most promising new drugs in the company's pipeline
You are receiving this email because you subscribed to this feed at blogtrottr.com.
No comments:
Post a Comment